Sammanfattning

Thymidine kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is upregulated during the S phase of the cell cycle and its presence in cells is an indicator of active cell proliferation. In studies since the 1980s, TK1 has been shown as a clinically valuable biomarker for the management of hematological malignancies. However, TK1 activity assays may underestimate serum TK1 in subjects with solid tumors limiting its sensitivity. The development of TK1 immunoassays has made the assay of TK1 more widely available and increased its applicability to solid tumor diseases. This paper will review TK1 as a tumor biomarker with emphasis on recent studies and technologies plus highlight its potential in drug discovery and as a therapeutic target.

Nyckelord

anti-TK1 antibodies; biomarker; breast cancer; cell culture; complementary biomarker; Hodgkin; leukemia; lymphoma; proliferation; prostate cancer; solid tumors; TK1; TK 210 ELISA; translational biomarker

Publicerad i

Biomarkers in Medicine
2018, Volym: 12, nummer: 9, sidor: 1035-1048
Utgivare: FUTURE MEDICINE LTD

SLU författare

• Jagarlamudi, Kiran Kumar

  • Institutionen för husdjurens biovetenskaper, Sveriges lantbruksuniversitet
    

Globala målen

SDG3 Säkerställa hälsosamma liv och främja välbefinnande för alla i alla åldrar


UKÄ forskningsämne

Medicinsk biovetenskap


Publikationens identifierare

DOI: https://doi.org/10.2217/bmm-2018-0157

Permanent länk till denna sida (URI)

https://res.slu.se/id/publ/96704